Menu

Berkeley CRISPR Inventors Get Another Important European Patent

This is the second patent the European Patent Office has issued to the institutions of Jennifer Doudna, Emmanuelle Charpentier, and colleagues.

Mar 12, 2018
Jim Daley

© BRYAN SATALINO

The European Patent Office (EPO) granted a patent for CRISPR-Cas9 applications to Emmanuelle Charpentier, a co-discoverer of CRISPR and the cofounder of ERS Genomics, the University of California, and the University of Vienna. The patent has very broad claims covering the use of the technology and is directed to applications that use a modified version of the Cas9 protein.

This is the second patent issued to the company by the EPO for the gene-editing technology. The first was granted last March for the use of CRISPR across prokaryotic and eukaryotic cells and organisms. The Broad Institute of MIT and Harvard University, on the other hand, has had less luck in Europe—in January, the EPO revoked a foundational patent belonging to the institution because it did not meet the agency’s requirement to establish that its scientists were the first to use CRISPR in eukaryotes.

See “UC Berkeley Receives CRISPR Patent in Europe

The latest patent “addresses yet another set of important applications of the CRISPR technology, which are becoming widely used in new drug discovery efforts and other areas of research,” says Eric Rhodes, CEO of ERS Genomics, in a press release. “This form of CRISPR is broadly enabling as it allows researchers to selectively repress or activate genes of interest to determine their function. It is the newest tool being used to discern the role of genes in disease, ultimately leading to new therapeutic applications.”

The most popular uses of this kind of CRISPR technology are inhibitory CRISPR (CRISPR-i) and activating CRISPR (CRISPR-a), according to the press release. The applications can be used to identify the roles genes play in various cellular processes and disease through a process known as single guide RNA (sgRNA) screening.

“It is gratifying to see CRISPR being deployed so broadly to help identify and understand so many new areas in biology,” Charpentier says in the press release. “The breadth of areas into which CRISPR is now being applied and the impact it is having is truly exciting.”

See “EPO Revokes Broad’s CRISPR Patent

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!